PolyNovo (ASX:PNV) - Cotización, noticias y análisis

Resumen de acción PNV

PolyNovo Limited desarrolla dispositivos médicos en Estados Unidos, Australia, Nueva Zelanda, Reino Unido, Irlanda, Singapur y a escala internacional.

Acerca de la empresa

PNV análisis fundamental
Puntuación del copo de nieve
Valoración	1/6
Crecimiento futuro	5/6
Resultados anteriores	2/6
Salud financiera	3/6
Dividendos	0/6

Recompensas

Cotiza un 10.7% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 39.08%

Ha pasado a ser rentable este año

Análisis de riesgos

Alto nivel de ganancias no monetarias

Competidores de PolyNovo Limited

Nanosonics

ASX:NAN

AU$833.2m

Ansell

ASX:ANN

AU$4.0b

SDI

ASX:SDI

AU$107.0m

Next Science

ASX:NXS

AU$74.5m

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de PolyNovo
Precios históricos de las acciones
Precio actual de la acción	AU$2.58
Máximo en 52 semanas	AU$2.78
Mínimo de 52 semanas	AU$1.10
Beta	1.63
11 mes Cambio	6.61%
Variación en 3 meses	25.85%
Cambio de 1 año	72.00%
3Variación en 3 años	20.56%
Variación en 5 años	42.94%
Variación desde la OPV	1,190.00%

Noticias y actualizaciones recientes

PolyNovo Limited's (ASX:PNV) P/S Is On The Mark

Aug 06

Recent updates

PolyNovo Limited (ASX:PNV) Shares Could Be 47% Below Their Intrinsic Value Estimate

Jan 08

Health Check: How Prudently Does PolyNovo (ASX:PNV) Use Debt?

Sep 22

When Should You Buy PolyNovo Limited (ASX:PNV)?

Jun 26

Are Investors Undervaluing PolyNovo Limited (ASX:PNV) By 29%?

May 30

Shareholders Should Be Pleased With PolyNovo Limited's (ASX:PNV) Price

Apr 18

Is It Too Late To Consider Buying PolyNovo Limited (ASX:PNV)?

Mar 23

Is PolyNovo Limited (ASX:PNV) Worth AU$2.6 Based On Its Intrinsic Value?

Feb 05

Returns At PolyNovo (ASX:PNV) Are On The Way Up

Nov 16

PolyNovo Limited's (ASX:PNV) Intrinsic Value Is Potentially 95% Above Its Share Price

Nov 01

What Does PolyNovo Limited's (ASX:PNV) Share Price Indicate?

Jul 29

PolyNovo (ASX:PNV) Is Looking To Continue Growing Its Returns On Capital

Jun 15

Estimating The Fair Value Of PolyNovo Limited (ASX:PNV)

May 16

We Think PolyNovo (ASX:PNV) Is Taking Some Risk With Its Debt

Apr 28

There's Been No Shortage Of Growth Recently For PolyNovo's (ASX:PNV) Returns On Capital

Mar 07

Is PolyNovo (ASX:PNV) Weighed On By Its Debt Load?

Dec 13

PolyNovo Limited's (ASX:PNV) CEO Compensation Looks Acceptable To Us And Here's Why

Oct 19

Is PolyNovo (ASX:PNV) Using Debt In A Risky Way?

May 08

News Flash: 7 Analysts Think PolyNovo Limited (ASX:PNV) Earnings Are Under Threat

Feb 27

Earnings Update: PolyNovo Limited (ASX:PNV) Just Reported And Analysts Are Trimming Their Forecasts

Feb 25

Is PolyNovo Limited (ASX:PNV) Potentially Undervalued?

Feb 17

These Analysts Think PolyNovo Limited's (ASX:PNV) Earnings Are Under Threat

Jan 14

Breakeven Is Near for PolyNovo Limited (ASX:PNV)

Dec 28

Rentabilidad de los accionistas

	PNV	AU Medical Equipment	Mercado AU
7D	1.6%	-6.1%	2.5%
1Y	72.0%	11.8%	10.6%

Rentabilidad vs. Industria: PNV superó a la industria Australian Medical Equipment, que obtuvo un rendimiento del 24.1% el año pasado.

Rentabilidad vs. Mercado: PNV superó al mercado Australian, que obtuvo un rendimiento del 9.6% el año pasado.

Volatilidad de los precios

Is PNV's price volatile compared to industry and market?
PNV volatility
PNV Average Weekly Movement	7.2%
Medical Equipment Industry Average Movement	10.0%
Market Average Movement	8.1%
10% most volatile stocks in AU Market	16.8%
10% least volatile stocks in AU Market	3.4%

Precio estable de las acciones: PNV no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de PNV (7%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1998	237	Swami Raote	www.polynovo.com

PolyNovo Limited desarrolla productos sanitarios en Estados Unidos, Australia, Nueva Zelanda, Reino Unido, Irlanda, Singapur y a escala internacional. La empresa ofrece la matriz temporalizante biodegradable NovoSorb, que se utiliza en una herida quirúrgica limpia totalmente desbridada para cerrar fisiológicamente la herida. También desarrolla dispositivos para la reparación de hernias y soluciones para la reconstrucción de hernias ventrales y de la pared abdominal compleja; NovoSorb Dermal Beta Cell Implant para alojar células de islotes pancreáticos en la piel; NovoSorb MTX para el tratamiento de heridas complejas variables; y productos para plásticos y dispositivos reconstructivos.

Resumen de fundamentos de PolyNovo Limited

¿Cómo se comparan los beneficios e ingresos de PolyNovo con su capitalización de mercado?
Estadísticas fundamentales de PNV
Capitalización bursátil	AU$1.78b
Beneficios(TTM)	AU$1.59m
Ingresos (TTM)	AU$83.47m

1,117x

Ratio precio-beneficio (PE)

21.3x

Ratio precio-ventas (PS)

¿Está PNV sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de PNV
Ingresos	AU$83.47m
Coste de los ingresos	AU$14.09m
Beneficio bruto	AU$69.38m
Otros gastos	AU$67.78m
Beneficios	AU$1.59m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

Aug 23, 2024

Beneficios por acción (BPA)	0.0023
Margen bruto	83.12%
Margen de beneficio neto	1.91%
Ratio deuda/patrimonio	3.4%

¿Cómo se ha desempeñado PNV a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción PNV

Recompensas

Análisis de riesgos

Competidores de PolyNovo Limited

ASX:NAN

AU$833.2m

ASX:ANN

AU$4.0b

ASX:SDI

AU$107.0m

ASX:NXS

AU$74.5m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

PolyNovo Limited's (ASX:PNV) P/S Is On The Mark

Now 24% undervalued

Price target increased by 8.8% to AU$2.37

Consensus EPS estimates increase by 15%

PolyNovo Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Insufficient new directors

Recent updates

PolyNovo Limited's (ASX:PNV) P/S Is On The Mark

Now 24% undervalued

Price target increased by 8.8% to AU$2.37

Consensus EPS estimates increase by 15%

PolyNovo Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Insufficient new directors

PolyNovo Limited's (ASX:PNV) P/S Is On The Mark

Now 21% undervalued

Now 23% undervalued

Now 20% undervalued

Price target increased by 9.7% to AU$2.14

When Should You Buy PolyNovo Limited (ASX:PNV)?

First half 2024 earnings released: EPS: AU$0.004 (vs AU$0.006 loss in 1H 2023)

Why Investors Shouldn't Be Surprised By PolyNovo Limited's (ASX:PNV) P/S

Price target increased by 7.4% to AU$1.95

PolyNovo Limited (ASX:PNV) Shares Could Be 47% Below Their Intrinsic Value Estimate

PolyNovo Limited, Annual General Meeting, Nov 03, 2023

Price target decreased by 9.5% to AU$1.88

Health Check: How Prudently Does PolyNovo (ASX:PNV) Use Debt?

Price target decreased by 7.8% to AU$2.07

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 65%, revenue upgraded

Forecast breakeven date pushed back to 2025

When Should You Buy PolyNovo Limited (ASX:PNV)?

Are Investors Undervaluing PolyNovo Limited (ASX:PNV) By 29%?

Price target decreased by 11% to AU$2.25

Forecast breakeven date pushed back to 2025

Shareholders Should Be Pleased With PolyNovo Limited's (ASX:PNV) Price

Independent Non-Executive Chairman recently sold AU$9.7m worth of stock

Is It Too Late To Consider Buying PolyNovo Limited (ASX:PNV)?

Now 23% undervalued after recent price drop

Forecast breakeven date moved forward to 2023

First half 2023 earnings released: AU$0.006 loss per share (vs AU$0.002 profit in 1H 2022)

PolyNovo Limited Announces Update on SynPath Diabetic Foot Ulcer Trial

PolyNovo Limited Announces Update on SynPath Diabetic Foot Ulcer Trial

Price target increased by 13% to AU$2.36

Consensus EPS estimates upgraded to AU$0.0002 loss

Is PolyNovo Limited (ASX:PNV) Worth AU$2.6 Based On Its Intrinsic Value?

Forecast breakeven date pushed back to 2024

Price target increased to AU$1.98

Price target increased to AU$1.90

Returns At PolyNovo (ASX:PNV) Are On The Way Up

PolyNovo Limited's (ASX:PNV) Intrinsic Value Is Potentially 95% Above Its Share Price

Independent Non-Executive Chairman recently bought AU$202k worth of stock

PolyNovo Limited, Annual General Meeting, Oct 28, 2022

PolyNovo Limited Announces Re-Designation of David McQuillan as Chief Technical and Scientific Officer

Price target increased to AU$1.68

Full year 2022 earnings: EPS misses analyst expectations

Now 21% undervalued

PolyNovo Limited Announces First Patient Enrolled in Clinical Trial of NovoSorb SynPath Treatment for Diabetic Foot Ulcers

PolyNovo Limited Announces CEO Changes

PolyNovo Limited Announces CEO Changes

What Does PolyNovo Limited's (ASX:PNV) Share Price Indicate?

Consensus forecasts updated

Now 21% undervalued

PolyNovo (ASX:PNV) Is Looking To Continue Growing Its Returns On Capital

Independent Non-Executive Chairman recently bought AU$956k worth of stock

Now 23% undervalued

Estimating The Fair Value Of PolyNovo Limited (ASX:PNV)